GlassScriptPhysician profile
John S Womble
NPI 1750379863
$11,286.48
in general payments reported to CMS, 2019-2025
40 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $1,277 · 2021: $1,662 · 2022: $1,343 · 2023: $1,694 · 2024: $2,005 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,546.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,683.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,541.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,240.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,065.80 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $875.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $766.47 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $503.27 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $470.87 | 2019-2025 | |
| Abbott Laboratories | $461.74 | 2019-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $459.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $455.90 | 2019-2023 | |
| Amgen INC. | $392.79 | 2019-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $206.35 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Abbvie INC. | $198.36 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $136.95 | 2022-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Womble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.